The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Comprehensive detection of myeloma genomic abnormalities
There have been great strides made in the identification of clinically relevant molecular subgroups in multiple myeloma. In this interview, Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses next-generation sequencing (NGS) for the detection of IGH translocations, relevant chromosomal gains and losses and novel genomic markers associated with poor outcomes, such as bi-allelic events involving TP53. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
